RNAi drug specialist ADARx raises $446M IPO
Why now
Thesis: RNAi IPO signals biotech issuance window reopening
Catalyst to watch: IPO pricing and post-listing trading
Main risk: Clinical-stage biotech IPOs can break issue
Why it matters
A $446M RNAi biotech IPO signals reopening risk appetite for clinical-stage drug developers.
Sources
- googlenews · news.google.com · 2026-09-25 00:37 UTC